Abstract
Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions. Background/Objectives: Recently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications. Methods: We have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication. Results: These InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means. Conclusions: The FERAD (ferritin–fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.
Original language | English (US) |
---|---|
Pages (from-to) | 726-739 |
Number of pages | 14 |
Journal | International Journal of Translational Medicine |
Volume | 4 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2024 |
Keywords
- Adnab-9
- FERAD ratio
- PD-L1 treatment outcomes
- absolute neutrophil/lymphocyte ratio
- cancer constellations
- p87
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- Medicine (miscellaneous)
- Genetics
- Immunology